tolvaptan has been researched along with Adverse Drug Event in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Quiroga, B; Torra, R | 1 |
| Howell, BA; Pellegrini, L; Shoda, LKM; Woodhead, JL | 1 |
| Beaudoin, JJ; Brock, WJ; Brouwer, KLR; Watkins, PB | 1 |
| Bonny, O; Martin, PY; Stucker, F | 1 |
| Howell, BA; Shoda, LKM; Siler, SQ; Watkins, PB; Woodhead, JL | 1 |
| Hussar, DA | 1 |
| Curtis, JL; Czerwiec, F; Filmyer, DM; Geboy, AG; Josiassen, RC; Ouyang, J; Shaughnessy, RA; Skuban, N | 1 |
3 review(s) available for tolvaptan and Adverse Drug Event
| Article | Year |
|---|---|
Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression.
Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan | 2022 |
[Clinical use of tolvaptan: a 2021 review].
Topics: Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Hyponatremia; Inappropriate ADH Syndrome; Tolvaptan | 2021 |
The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury.
Topics: Animals; Benzazepines; Chemical and Drug Induced Liver Injury; Chromans; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Biological; Thiazolidinediones; Tolvaptan; Troglitazone | 2017 |
1 trial(s) available for tolvaptan and Adverse Drug Event
| Article | Year |
|---|---|
Vaptans: a potential new approach for treating chronic hyponatremia in psychotic patients.
Topics: Administration, Oral; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Hyponatremia; Long-Term Care; Male; Middle Aged; Psychotic Disorders; Sodium; Tolvaptan; Treatment Outcome | 2012 |
4 other study(ies) available for tolvaptan and Adverse Drug Event
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling.
Topics: Benzamides; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Theoretical; Polycystic Kidney, Autosomal Dominant; Pyrroles; Tolvaptan | 2020 |
Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity.
Topics: Bile Acids and Salts; Biological Transport; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Hepatocytes; Humans; Liver; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2021 |
New Drugs2010, PART 1.
Topics: Acetamides; Antibodies, Monoclonal; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azepines; Benzazepines; Benzhydryl Compounds; Benzyl Alcohol; Benzylamines; Cyclams; Cyclopropanes; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Ethanolamines; Everolimus; Febuxostat; Fluorenes; Fluoroquinolones; Gout Suppressants; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Indoles; Lacosamide; Milnacipran; Oligopeptides; Phenols; Selective Serotonin Reuptake Inhibitors; Sirolimus; Tapentadol; Thiazoles; Tolvaptan; Triazoles | 2010 |